APLS News and Press, Apellis Pharmaceuticals Inc. From 05/23/24

2024-05-23 08:00:11 ET Derek Archila from Wells Fargo issued a price target of $48.00 for APLS on 2024-05-23 07:10:00. The adjusted price target was set to $48.00. At the time of the announcement, APLS was trading at $43.6. The overall price target consensus is at $76.38...

2024-05-14 08:28:39 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks Apellis stock sell-off over Syfovre sales "overdone," says Citi Read the full article on Seeking Alpha For further details see: Ap...

Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments...

2024-05-13 23:20:00 ET Summary Apellis Pharmaceuticals' stock struggles post-vasculitis scare from Syfovre injections, impacting its initial market penetration. Syfovre continues to lead in GA treatment sales, but faces competition and concerns about its long-term efficacy and saf...

2024-05-08 13:38:51 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnin...

2024-05-07 16:02:13 ET Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Conference Call May 07, 2024 08:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Ba...

2024-05-07 07:16:06 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Eye Disease Drug Syfovre O...

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than J...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 11:08:27 ET Major earnings expected before the bell on Tuesday include: BP p.l.c. ( BP ) Datadog ( DDOG ) The Walt Disney ( DIS ) Duke Energy ( DUK ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...